ADMA Biologics Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
647
- Stock Symbol
-
ADMA
- Investments
-
2
- Share Price
-
$13.69
- (As of Friday Closing)
ADMA Biologics General Information
Description
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
Contact Information
Website
www.admabiologics.comCorporate Office
- 465 Route 17 South
- Ramsey, NJ 07446
- United States
Corporate Office
- 465 Route 17 South
- Ramsey, NJ 07446
- United States
ADMA Biologics Stock Performance
As of 13-Nov-2026, ADMA Biologics’s stock price is $13.69. Its current market cap is $3.03B with 222M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $13.69 | $13.24 | $7.21 - $20.46 | $3.03B | 222M | 3.11M | $0.79 |
ADMA Biologics Financials Summary
As of 30-Sep-2026, ADMA Biologics has a trailing 12-month revenue of $519M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,314,385 | 4,362,817 | 4,078,770 | 1,100,191 |
| Revenue | 519,153 | 510,173 | 426,454 | 258,215 |
| EBITDA | 248,485 | 195,991 | 145,592 | 3,503 |
| Net Income | 182,413 | 146,930 | 197,673 | (28,239) |
| Total Assets | 732,485 | 624,242 | 488,678 | 329,182 |
| Total Debt | 202,804 | 79,885 | 82,116 | 141,418 |
ADMA Biologics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ADMA Biologics Comparisons
Industry
Financing
Details
ADMA Biologics Competitors (19)
One of ADMA Biologics’s 19 competitors is Roche, a Corporation company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Roche | Corporation | Basel, Switzerland | ||||
| Grifols | Corporation | Barcelona, Spain | ||||
| Nevian Lifescience | Corporate Backed or Acquired | Dhaka, Bangladesh | ||||
| Evonile Pharma | Private Equity-Backed | Mumbai, India | ||||
| Ipsen | Formerly PE-Backed | Paris, France |
ADMA Biologics Patents
ADMA Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4402178-A2 | Conjugated antibodies for treating diseases | Pending | 16-Sep-2021 | ||
| EP-4402178-A4 | Conjugated antibodies for treating diseases | Pending | 16-Sep-2021 | ||
| WO-2023043861-A2 | Conjugated antibodies for treating diseases | Inactive | 16-Sep-2021 | ||
| WO-2023043861-A3 | Conjugated antibodies for treating diseases | Inactive | 16-Sep-2021 | ||
| WO-2022031611-A1 | Compositions and methods for determining coronavirus neutralization titers | Inactive | 03-Aug-2020 | G01N33/56983 |
ADMA Biologics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ADMA Biologics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ADMA Biologics Investments (2)
ADMA Biologics’s most recent deal was a Corporate Asset Purchase with ADMA Biologics (5-Acre Land Property in Boca Raton, Florida) for . The deal was made on 01-Jul-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ADMA Biologics (5-Acre Land Property in Boca Raton, Florida) | 01-Jul-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Biotest Pharmaceuticals (certain manufacturing and therapy-related assets) | 06-Jun-2017 | Corporate Asset Purchase | Buildings and Property |
ADMA Biologics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
31.07 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
ADMA Biologics FAQs
-
When was ADMA Biologics founded?
ADMA Biologics was founded in 2004.
-
Where is ADMA Biologics headquartered?
ADMA Biologics is headquartered in Ramsey, NJ.
-
What is the size of ADMA Biologics?
ADMA Biologics has 647 total employees.
-
What industry is ADMA Biologics in?
ADMA Biologics’s primary industry is Biotechnology.
-
Is ADMA Biologics a private or public company?
ADMA Biologics is a Public company.
-
What is ADMA Biologics’s stock symbol?
The ticker symbol for ADMA Biologics is ADMA.
-
What is the current stock price of ADMA Biologics?
As of 13-Nov-2026 the stock price of ADMA Biologics is $13.69.
-
What is the current market cap of ADMA Biologics?
The current market capitalization of ADMA Biologics is $3.03B.
-
What is ADMA Biologics’s current revenue?
The trailing twelve month revenue for ADMA Biologics is $519M.
-
Who are ADMA Biologics’s competitors?
Roche, Grifols, Nevian Lifescience, Evonile Pharma, and Ipsen are some of the 19 competitors of ADMA Biologics.
-
What is ADMA Biologics’s annual earnings per share (EPS)?
ADMA Biologics’s EPS for 12 months was $0.79.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
